相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPYD polymorphisms c.496A > G, c.2194G > A and c.85T > C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols
Nada Bozina et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
Mirjam de With et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity
Seid Hamzic et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events
Theodore J. Wigle et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Theodore J. Wigle et al.
PHARMACEUTICS (2019)
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Ayman Madi et al.
EUROPEAN JOURNAL OF CANCER (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
New advances in DPYD genotype and risk of severe toxicity under capecitabine
Marie-Christine Etienne-Grimaldi et al.
PLOS ONE (2017)
DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia
Xiao-Qiang Zhao et al.
TUMOR BIOLOGY (2016)
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
Valerie Boige et al.
JAMA ONCOLOGY (2016)
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
Felicia Stefania Falvella et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
M. Joerger et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
Giuseppe Toffoli et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
Dan Rosmarin et al.
GUT (2015)
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Tanja K. Froehlich et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
Dan Rosmarin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
A. Loganayagam et al.
BRITISH JOURNAL OF CANCER (2013)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
Ursula Amstutz et al.
PHARMACOGENOMICS (2009)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
Eva Gross et al.
PLOS ONE (2008)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
Keiko Maekawa et al.
JOURNAL OF HUMAN GENETICS (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
分享论文
